Uncategorized
Racing for the cure
admin | November 1, 2019
This material is a Marketing Communication and does not constitute Independent Investment Research.
The U.S. economy remains on a dual track. Domestically focused sectors such as consumer spending, labor market, services and housing continue to do well. More globally oriented sectors such as manufacturing, business investment and exports have struggled under the specter of trade policy uncertainty and on-again-off-again tariffs. A central question for the economic outlook is which side will win out. Will the softness globally eventually do in the consumer, or will the stalwart consumer rescue the languishing business sector?
Standoff
In some ways, the current performance of the U.S. economy feels a little like one of those movies where a super-virus breaks out, and there is a frenzied race to come up with a cure before the human race is wiped out. The stakes are perhaps not quite as high, but a central theme of 2019 has been the contrast between globally-oriented sectors of the economy, which have been softening, and domestically-focused areas, which continue to be robust. Think of the manufacturing sector as the contagious infected population, and the consumer sector as the still-virus-free population. Will the contraction in the manufacturing sector infect the up-to-now healthy parts of the economy, or will the vigor of domestically-focused industries drag the factory sector out of its funk?
Recession scenario
The blueprint for the unhappy scenario is pretty clear. Businesses, spooked by trade policy uncertainty, tariffs, and a soft global economy, have put a halt to a myriad of investment projects. Business fixed investment declined in real terms in both Q2 and Q3. The path for this virus to cross over to the healthy population would be if businesses, in their caution, also begin to put a hold on hiring, or, worse yet, lay employees off. Such a development would presumably impact household income growth as well as consumer confidence, jeopardizing the remainder of the economy.
The labor market data do not yet provide much support for this scenario. While payroll gains have slowed, this may also reflect the scarcity of available workers with the unemployment rate at a 50-year low. Moreover, initial claims have not moved higher this year and, in fact, also remain near 50-year lows.
Chairman Powell was specifically asked about this scenario in his October 30 press conference, and he responded that “we don’t see it yet.” He cited positive labor market data as well as anecdotal reports from “consumer-facing companies” that were predominantly positive. In other words, so far, so good.
The happy ending scenario
Some of the movies in the outbreak genre end with society entirely wiped out, but most have a happy, or at least a hopeful, ending. In our economic thriller, the positive outcome would entail a recovery in the manufacturing sector, restoring to health the sectors that have been depressed this year by trade policy uncertainty and weak overseas demand.
There are reasons for optimism. In fact, an argument could be made that we have just endured the worst of it. There are three factors that could contribute to a pickup in activity going forward.
First, the GM strike, which stretched from mid-September until late October, temporarily depressed manufacturing activity. The September readings for industrial production, for example, were clearly impacted, and the October figures are likely to be even worse. However, with the strike settled, GM will likely schedule a lot of overtime and try to rebuild its inventories of popular models over the next few months. Moreover, Ford and the UAW reached a tentative deal on a contract this week, so it looks like we may avoid a repeat of the work stoppage that GM endured (though a deal still has to be worked out at Chrysler).
Second, the travails of the Boeing 737 MAX are not going to last forever, though it may seem that way. Since the MAX was grounded early this year, Boeing has halted production of the model, and airlines have not been booking any new MAX planes. The economic impact has been considerable. Domestic investment in aircraft has plunged by more than half, from $53 billion annualized in the fourth quarter of last year to $25 billion in the third quarter. Similarly, exports of civilian aircraft and parts have dipped from $138 billion to $119 billion. The Boeing issues have lowered GDP by almost $50 billion so far this year. Presuming that the MAX is recertified early next year and production returns to normal by mid-2020, we could see a tailwind to business investment/manufacturing/exports that adds as much as half a percentage point to the pace of GDP growth over two or three quarters.
Finally, there is the biggest driver of all of the weakness in globally-facing sectors, the U.S.-China trade war. We have seen numerous swings in sentiment regarding the trade outlook this year, but most of the movements have been negative since talks broke off in the spring. The August-September period appears to have been the worst so far, as President Trump announced new tariffs and the Chinese retaliated.
More recently, the two sides came together and reached a tentative Phase One agreement that is scheduled to be formally ratified in November. This all hews to my long-held guess at how the trade negotiations would evolve relative to the election cycle. President Trump took a belligerent tone in the summer, seeking to cement his image as someone who would challenge China, but he needs the U.S. economy to be at its best during the 2020 presidential campaign, so he was always going to need to make nice by late 2019 or perhaps early 2020.
The situation remains unpredictable, but I would be surprised if things return to the gloomy days of August and September any time before next November. If this hypothesis is correct, then business sentiment should gradually improve (another potential positive on this front would be Congressional approval of the USMCA), and business investment would presumably rebound to some degree over the next few quarters.
Conclusion
At this point in our outbreak movie, there is reason for hope but the situation is still touch-and-go. However, there are reasons to be optimistic that the past few months will, in retrospect, prove to be the worst of the cycle for globally-facing sectors. The prospects for overseas demand remain mediocre at best, so even the happy ending scenario is not an overwhelming victory (after all, at the end of outbreak movies, those who succumb to the virus are still dead after a cure is finally found), but it is not hard to construct a scenario where real GDP growth returns to the solidly above-trend 2.5% pace seen for most of 2018 and the first half of 2019.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2026 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
Important disclaimers for clients in the EU and UK
This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).
The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.
This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.
This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.
This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.
